

FINALISTS 2022

Private Financing Deal of the Year

This Scrip Award seeks to reward successful and creative fundraising by private pharma and biotech companies.

SCRIP AWARDS 2022

30 NOVEMBER 2022 · ROYAL LANCASTER, LONDON

Engitix Therapeutics'

\$54m Series A financing

In early 2022, Engitix announced the simultaneous closing of a \$54m series A financing alongside a strategic collaboration with Dompé. Engitix has a portfolio of internal and partnered drug discovery programmes in fibrosis and solid tumors developed using its pioneering proprietary human extracellular matrix drug target discovery platform. The use of more physiologically relevant human in vitro models is transforming the ability to identify new targets and enable a more accurate prediction of drug efficacy.

Mestag Therapeutics'

\$45m seed funding

Mestag Therapeutics' ground-breaking work exploring the potentially critical role of fibroblasts in inflammatory disease and oncology was recognized by prestigious US and European investors with the closing of an oversubscribed Seed extension announced in August 2021, bringing the total round to \$45m. The funding underlined Mestag's growing profile as an innovator in the potentially transformational field of fibroblast biology, and follows a target discovery, option and license agreement with Janssen Biotech.

Microbiotica's

£50m Series B financing

Microbiotica announced a £50m Series B financing in March 2022, the largest microbiome-related round in Europe and one of the largest globally, despite challenges in this emerging new field. This was a crucial event in the scaling of the company, enabling the transition to the clinic (two Phase Ib trials in 2023), building the team, and expanding the discovery pipeline. It was also an important milestone for the microbiome sector.

OMass Therapeutics'

\$100m Series B financing

OMass Therapeutics announced in April an oversubscribed \$100m series B, the largest ever raised by a UK small-molecule biotechnology company. The round was co-led by an international syndicate of new investors, including GV, Northpond Ventures and Sanofi Ventures, alongside current investors Syncona and Oxford Science Enterprises. The proceeds will be used to advance its portfolio of novel drugs from its proprietary drug discovery platform, OdyssION, against highly-validated, yet intractable or inadequately drugged targets.

Precirix's

€80m Series B financing

In March, Precirix raised €80m in a Series B to advance its pipeline of precision radiopharmaceuticals developed using camelid single-domain antibodies, led by new investors INKEF Capital, Jeito Capital and Forbion. The company's existing shareholders as well as the seed investors also participated in the financing round, the proceeds of which will fund the advancement of lead candidate CAM-H2 through its ongoing Phase I/II study, and the addition of novel radiopharmaceuticals to the clinic.

SalioGen Therapeutics'

\$130m Series B financing

In January, SalioGen completed an oversubscribed and up-sized Series B financing of over \$130m that far exceeded its original \$75m target. Given deteriorating market conditions, the team decided not only to execute highly curated investor outreach but also to preemptively structure the financing to allow additional capital commitments. SalioGen plans to use the proceeds to build its Gene Coding platform, to expand its team and generate sufficient data to take its plans to regulators.

Winners are announced at the Awards ceremony and dinner on Wednesday 30th November at the Royal Lancaster Hotel, London.